Five-Years After PFO Closure: Procedural Safety and Effectiveness

Five-year outcomes of the randomized REDUCE study showed a continuous benefit from patent foramen ovale (PFO) closure compared with antiplatelet agents to prevent cryptogenic strokes.

5 años del cierre del FOP

The most important aspect of this result seems to be the idea that PFO closure in selected patients offers durable benefit with guaranteed long-term safety.

The original results from REDUCE were presented at the European Stroke Organization Conference in 2017. There, the study demonstrated a 77% recurrent ischemic stroke risk reduction with PFO closure vs. antiplatelet therapy at about 3.2 years of follow-up.

The results presented now in NEJM show that the benefit from this intervention is sustained to prevent recurrent stroke at 5-years of follow-up (1.8% vs. 5.4%; hazard ratio: 0.31; 95% confidence interval: 0.13 to 0.76). In absolute terms, the advantage is 3.6%; therefore, 25 PFO closures are needed to prevent a stroke.

Other safety endpoints like death, major bleeding, and deep venous thrombosis were similar between groups without any further complications related to the device.


Read also: Major Cause of Myocardial Injury by COVID-19.


The only difference against the closing device was a higher risk of atrial fibrillation (6.8% vs. 0.4%). These data require further follow-up, as the increased chances of atrial fibrillation could dilute the benefit in terms of stroke and the increased need for anticoagulation could modify bleeding rates against the device.

Investigators from the REDUCE trial are collaborating with investigators from other large studies on the topic (RESPECT, CLOSE, CLOSURE I, PF, DEFENSE PFO) to produce a large meta-analysis that will shed light on predictors of atrial fibrillation, late stroke, and other complications.

Conclusion

The foramen ovale closure device maintained its superiority in preventing recurrent strokes vs. medical treatment at 5 years of follow-up in patients with cryptogenic stroke and patent foramen ovale.

nejmc2033779

Original Title: Five-year outcomes of PFO closure or antiplatelet therapy for cryptogenic stroke.

Reference: Kasner SE et al. N Engl J Med. 2021;384:970-971.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Percutaneous Tricuspid Valve Replacement with Lux-Valve

Tricuspid regurgitation (TR) is a condition associated with poor quality of life, frequent hospitalizations due to heart failure, and increased mortality, even under optimal...

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Another Blow for Intra-Aortic Balloon Pumo Counterpulsation? Randomized Study on Its Use in Chronic Heart Failure Progressing to Cardiogenic Shock

Cardiogenic shock (CS) remains a condition with extremely high mortality (around 50%). While most therapies for this pathology have been studied in CS secondary...